

Ref. No: 289170921  
From: Research  
Date: 17/09/21  
Subject: Dermatology department

## REQUEST

I have a Freedom of Information request and I would greatly appreciate if you could answer the below two questions:

Q1. Could you please provide the numbers of patients treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab – Humira
- Adalimumab Biosimilar
- Apremilast
- Bimekizumab
- Brodalumab
- Certolizumab
- Dimethyl fumarate
- Etanercept – Enbrel
- Etanercept Biosimilar
- Guselkumab
- Infliximab – Remicade
- Infliximab Biosimilar
- Ixekizumab
- Risankizumab
- Secukinumab
- Tildrakizumab
- Ustekinumab

Q2. How many patients have been treated for Psoriasis ONLY in the last three months with the following:

- Ciclosporin
- Methotrexate - any form and strength
- Methotrexate injections 15mg and above

## RESPONSE

### Pharmacy Response Question 1

- Adalimumab – Humira **8**
- Adalimumab Biosimilar **46**
- Apremilast **57**
- Bimekizumab **0**
- Brodalumab **0**
- Certolizumab **0**
- Dimethyl fumarate **9**
- Etanercept – Enbrel **0**
- Etanercept Biosimilar **0**
- Guselkumab **7**
- Infliximab – Remicade **0**
- Infliximab Biosimilar **0**
- Ixekizumab \***<5**
- Risankizumab\***<5**
- Secukinumab \***<5**
- Tildrakizumab **0**
- Ustekinumab **22**

Please note \***<5** has been added where the number of patients is 5 or less, this information has been redacted to protect patient confidentiality and to ensure that patients cannot be identified.

### Pharmacy Response Question 2

We cannot answer this question as we do not record the indications.